Skip to content

Medical emergency? What to do

Neuroprotective agent improves outcome after ischemic stroke

3-RXPublished February 13, 20062 min read

Key points

  • The first neuroprotective agent to show positive results in a phase 3 trial significantly reduces disability after ischemic stroke, according to results of the Stroke-Acute Ischemic NXY Treatment (SAINT I) trial published in the February 9, 2006 issue of The New England Journal of Medicine.
  • James Grotta, of the University of Texas at Houston, and his fellow SAINT I investigators report that disability was significantly reduced in the treatment arm at 90 days.
  • "Neuroprotective drugs don't do anything to the artery with regards to recanalization or increased flow," Dr.
  • Gregory del Zoppa cautions that while promising, the results with NXY-059 might not yield a significant benefit in the bigger picture of ischemic stroke.

The first neuroprotective agent to show positive results in a phase 3 trial significantly reduces disability after ischemic stroke, according to results of the Stroke-Acute Ischemic NXY Treatment (SAINT I) trial published in the February 9, 2006 issue of The New England Journal of Medicine.

The trial involved 1,699 patients with acute ischemic stroke randomly assigned to receive either a 72-hour infusion of NXY-059 (AstraZeneca, Wilmington, DE) or placebo within six hours of the onset of ischemic stroke. The primary endpoint was disability at 90 days as measured by the Rankin scale, with 0 meaning no residual disability and 5 indicating bedbound and requiring constant care.

Dr. James Grotta, of the University of Texas at Houston, and his fellow SAINT I investigators report that disability was significantly reduced in the treatment arm at 90 days. The odds ratio for improvement was 1.20 across all categories of the Rankin scale.

However, mortality and rates of serious and non-serious adverse events were similar in both arms of the study. Active treatment did not result in improvements in neurological function compared with placebo. The subset of patients who also received alteplase had a lower incidence of intracranial hemorrhage.

"Neuroprotective drugs don't do anything to the artery with regards to recanalization or increased flow," Dr. Grotta told Reuters Health. "The mechanism of action is to correct imbalances at the cellular level that result from the blockage." The drug soaks up free radicals.

Dr. Grotta said that SAINT II, involving 3,200 patients, is ongoing to confirm the SAINT I results. Results of SAINT II are expected in 2007. "If the results are positive, then we can expect FDA approval," Dr. Grotta remarked.

Editorialist Dr. Gregory del Zoppa cautions that while promising, the results with NXY-059 might not yield a significant benefit in the bigger picture of ischemic stroke. He writes "effective strategies for ischemic stroke may need to provide protection to the entire neurovascular unit," rather than reducing neuronal cell damage alone.

N Engl J Med 2006;354:588-600.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underStroke

Keep reading

Stroke

Useful stroke trials left unpublished

An investigation into unpublished stroke research data has revealed that 19.6% of completed clinical trials, which could potentially influence patient care, are not published in full. Researchers writing in BioMed…

3 min read

Trauma

Different strokes help tissue heal

Using simple handheld tools, physical therapist Laurie Eickhoff carefully rubs patient Lisa Maharry's leg to treat her Achilles injury with a new therapy intended to stimulate the body's normal healing process.…

3 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.